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Abstract: Src is the representative member of the Src-family kinases (SFKs), a group of tyrosine kinases
involved in several cellular processes. Its main function has been for long confined to the plasma
membrane/cytoplasm compartment, being a myristoylated protein anchored to the cell membrane
and functioning downstream to receptors, most of them lacking intrinsic kinase activity. In the last
decades, new roles for some SFKs have been described in the nuclear compartment, suggesting
that these proteins can also be involved in directly regulating gene transcription or nucleoskeleton
architecture. In this review, we focused on those nuclear functions specifically attributable to Src, by
considering its function as both tyrosine kinase and adapting molecule. In particular, we addressed
the Src involvement in physiological as well as in pathological conditions, especially in tumors.
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1. Introduction
The members of the Src family of protein tyrosine kinases (SFKs) are expressed in all mammalian
cells, where they are implicated in pivotal physiological cellular processes as proliferation, migration,
differentiation and survival, as well as in pathological cancer onset and progression, when overactivated.
These are non-receptor tyrosine kinases that, once activated by external stimuli acting on receptors for
growth factors, cytokines, steroid hormones, on G protein-coupled receptors and adhesion proteins,
start a signaling cascade leading to widespread effects [1]. The family consists of eleven members,
among which Src is the prototype enzyme: the members of the main group (Src, Yes, Fyn, Fgr, Blk,
Hck, Lck, and Lyn) are closely related, while Frk, Srm, and Brk constitute a more distantly related
group. Among them, Src, Yes, and Fyn are expressed in mammals in a ubiquitous manner, while
the expression pattern of the other members is tissue and/or cell restricted [2]. These SFKs share
high homologous structure consisting of four consecutive Src Homology (SH) domains: an SH4
membrane-targeting region at their N-terminus, that can be myristoylated and/or palmitoylated to
allow membrane localization; an intrinsically disordered unique domain, which exhibit strong sequence
divergence among SFK members; the regulatory SH-2 and SH-3 domains precede a large catalytic
C-terminal domain (SH1) with the hallmark of Src kinases, an autoinhibitory phosphorylation site that
is the Y527 residue in human Src (Figure 1) [3].
All members of the Src family kinases present with myristoylation at the N-terminus [3].
Myristoylation is an irreversible modification that occurs cotranslationally and is catalyzed by the
N-myristoyl transferases (NMTs). The 14-carbon myristoyl group attached to a glycine residue of the
SH4 domain is necessary but not sufficient to anchor SFKs to the plasma membrane, given that a
second signal is required. For the other SFKs, a palmitoylation motif functions as the second signal to
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be targeted to the membrane, while Src requires a polybasic cluster of amino acids to interacts with
the inner leaflet of the membrane bilayer. Recent evidence demonstrates that dimerization as well
as kinase activity and substrate phosphorylation are mediated by the first domains along with the
N-terminal myristoylation [4–6]. Le Roux and coauthors performed a kinetic characterization of the Src
binding to the lipidic layer of the plasma membrane, demonstrating that the first N-terminal domains
of myristoylated Src are involved in the formation of a stable dimer whose membrane binding is much
stronger than the monomeric Src form. Interestingly, the equilibrium between monomeric (labile) and
dimeric (persistent) form of myristoylated Src can regulates Src localization and the downstream Src
signaling at specific membrane sites [4,7,8].
The function of SH2 domain is to specifically bind a target protein by its phosphorylated tyrosine
residue within a longer peptide motif, thus allowing SH2 domain-containing proteins to interact.
The recognition of the phospho-tyrosine residues within the SH2 domain is guaranteed by a universally
conserved arginine residue needed to form the proper electrostatic interactions with the phosphorylated
tyrosine [3].
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The SH3 domain is crucial for protein-protein interaction by mediating assembly of specific protein
complexes, typically via binding to proline-rich peptides bearing the ‘PxxP’ motif in their respective
binding partner [9].
The catalytic SH1 domain at the C-terminus contains the site of activating tyrosine phosphorylation,
residue Y419 in human Src kinase. This domain, the most conserved in all tyrosine kinases, contains an
ATP-binding pocket and the tyrosine-specific protein kinase activity [10].
Inactive Src is maintained in a closed conformation, in which the SH2 domain is engaged with the
phosphorylated autoinhibitory residue, the SH3 domain binds the SH2-kinase linker sequence and the
activating-tyrosine residue is dephosphorylated. Indeed, it has been demonstrated that the inactive
conformation of the kinase domain is energetically more favorable when it is not phosphorylated.
The work by Xu et al. on the crystal structure of Src demonstrated that the unphosphorylated activation
segment adopts an α-helical structure that contributes to stabilize the closed conformation of Src.
Therefore, their hypothesis is that any effector interaction that disrupts this helical structure would
bring about the relief of negative constraint and make the enzyme temporally active [11]. In this context,
the adaptor protein Shc seems to be involved in the structural changes required to activate Src. Indeed,
Shc can bind Src when its activation segments are unphosphorylated, inducing a structural alteration
of the activation segment conformation leading to the relief of the negative constraint of the catalytic
domain. This event allows the autophosphorylation of the activation segment, thereby guarantee the
stabilization of the catalytic domain active conformation [12]. Therefore, the dephosphorylation of
autoinhibitory tyrosine disrupts its intramolecular interaction with the SH2 domain, leading to an
open conformational state that allows autophosphorylation of activating-tyrosine residue, resulting in
Src activation [13–16].
Once autophosphorylation has occurred, the activation of the kinase domain required large
rearrangements in its orientation. Autophosphorylation displaced the regulatory domains that become
more flexible and establish a strong cross-talk with the kinase domain, which in turn gains rigidity,
leading to the stabilization of the ATP binding site [13].
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By modulating the phosphorylation status of the SFK inhibitory tyrosine residue, several tyrosine
kinases and phosphatases are involved in the fine-tuning regulation of Src and other kinase activation.
Indeed, phosphorylation of Y530 can be removed by several protein phosphatases, thereby function as
activators of Src, such as protein tyrosine phosphatase-α (PTPα), PTP1, SH2-containing phosphatase 1
(SHP1) and SHP2 [17]. The upstream signals involved in the activation of such protein phosphatases
seem to be cell-specific. For example, PTP1B, a ubiquitously expressed protein phosphatase, is involved
in dephosphotylating Src pY530 in breast cancer cell lines but not in the normal cell counterpart [18].
On the other hand, the non-receptor tyrosine kinase Csk serves as an indispensable negative regulator
of the SFKs by specifically phosphorylating their negative regulatory site, thereby suppressing their
activation. The activation of Csk depends on several upstream mechanisms, the first of which is the
membrane anchoring mediated by scaffolding proteins, since Csk lacks the transmembrane domain
allowing the anchorage to the lipidic bilayer, where the most of SFKs reside [19].
Src and the other tyrosine kinases of the family are downstream targets for cell surface receptors,
and function as a link between the membrane receptors and the cytoplasmic signaling machinery,
thereby regulating many fundamental cellular processes, including cell growth, differentiation, cell
shape, migration and survival, and specialized cell signals [2]. In this context, it is worth mentioning
that, although the ubiquitous expression of Src, the specific deletion of its gene in an animal model (Src
knock-out mice) leads to a peculiar bone osteopetrotic phenotype [20], highlighting the crucial role of
this tyrosine kinase in the cells of the bone tissue, both on osteoclast [21,22] and on osteoblast side [23],
and the evidence that the other SFK members are able to vicariate the lack of Src in the other tissues.
2. Nuclear Functions of SFKs other than Src
The main functions exerted by SFKs are related to their membrane and cytoplasmic localizations.
As downstream targets of receptor tyrosine kinases (RTKs), SFKs affect cell proliferation via the
Ras/ERK/MAPK pathway and regulate gene expression and angiogenesis via transcription factors
such as STAT molecules. In their cytoplasmic functions, SFKs can interact with integrins, actins,
GTPase-activating proteins, scaffold proteins such as p130CAS and paxillin, and kinases such as focal
adhesion kinases, thereby affecting cell adhesion and migration [1]. Beside these membrane/cytoplasmic
functions, SFKs have been described in other subcellular compartments, as the nucleus, the Golgi
apparatus, late endosomes/lysosomes and mitochondria [24–28]. Subcellular distribution of SFKs other
than Src are reported in the Table 1.
Table 1. Subcellular distribution of Src-family kinases (SFKs) other than Src. CM: cell membrane;





Yes X X Dubois et al. [29]
Fyn X X X Saito et al. [30] - Matsushima et al. [31]
Fgr X X Dwyer et al. [32]
Lck X Stephen et al. [33]
Hck X X Poh et al. [34]
Blk X Petersen et al. [35]
Srm X Serfas and Tyner [36]
Brk X X X Derry et al. [37]
Lyn X X X Yoshida et al. [38]
Frk (Rak) X X Ogunbolude et al. [39] - Kim et al. [40]
Matsushima and coauthors have demonstrated a nuclear function for the tyrosine kinase Fyn in
cardiomyocytes. Among the nicotinamide adenine dinucleotide phosphate (NADPH) oxidases, the
main sources of reactive oxygen species (ROS) in the cardiovascular system [41], NOX4 expression
and activity is fine tuning regulated in cardiomyocytes, playing a crucial role in the development of
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cardiac remodeling and injury. Authors showed that Fyn, once activated by oxidative stress, binds the
c-terminal of NOX4 and colocalizes with it in perinuclear mitochondria, endoplasmic reticulum and
nucleus. Doing this, Fyn serves as a negative feedback regulator of NOX4 in cardiomyocytes during
cardiac remodeling [31].
Among SFKs, also Brk (human breast tumor kinase) and its orthologue Sik (mouse Src-related
intestinal kinase) have been described to exert some nuclear functions. These tyrosine kinases are
distantly related to the Src family, having a similar structure but lacking the myristoylation signal.
Prior to Derry et al. work, no substrates of Sik and Brk had been identified. Authors demonstrated
that Sam68 (Src associated in mitosis; 68 kDa), a RNA- binding protein that was first identified as a
major target of Src during mitosis [42], can be phosphorylated by Brk/Sik within the nucleus, thereby
negatively regulating its RNA binding activity [37]. Therefore, these data showed that, in addition to
Sam68 phosphorylation by SFKs during mitosis, Brk/Sik can phosphorylate Sam68 and regulate its
activity within the nucleus during the rest of the cell cycle.
Among the SFKs exerting nuclear functions, the Lyn tyrosine kinase is known to be involved
in the cellular response that includes cell cycle arrest, activation of DNA repair, and, in the event of
irreparable damage, induction of apoptosis [43]. The work by Yoshida and coauthors describes Lyn
involvement in the induction of the stress-activated protein kinase (SAPK), and that this pathway is
functional in the induction of apoptosis by genotoxic agents [38].
In the context of cellular response to DNA damage, Rak tyrosine kinase has a peculiar role given
that, unlike Src and the most of the other SFKs, it functions as a tumor suppressor in human cancer [39].
Indeed, it has been demonstrated a critical role of Fyn-related kinase (Frk)/Rak in the maintenance of
genomic stability, at least in part, through protecting BRCA1 [40].
3. Src Translocation into the Nucleus
Some Src family tyrosine kinases have been described to reside in the nucleus, although there
is a lack of nuclear localization signal (NLS). The NLS is a short sequence of positively charged
lysines or arginines exposed on the protein surface that “tags” a protein for import into the cell
nucleus by nuclear transport [44]. Canonical NLS are not present on SFK amino acid sequence,
thus suggesting that these proteins may enter the nucleus through a not-canonical NLS or by an
alternative way from active transport. In 1993, David-Pfeuty and coauthors suggested the intriguing
hypothesis that nonmyristoylated proteins can readily accumulate into the nucleus, thereby attributing
to myristoylation a role in preventing unregulated nuclear transport of proteins. They also raise the
possibility that, in specific circumstances, a subfraction of Src may translocate into the nucleus where it
exerts peculiar functions, thus behaving like its nonmyristoylated counterpart [45].
In support of David-Pfeuty hypothesis, we recently demonstrated that Src nuclear localization
in osteoblasts and osteosarcoma cell lines is related to the myristoylation status of the cells. Indeed,
low aggressive osteosarcoma SaOS-2 cells show high content of nuclear Src with a low myristoylation
and low expression of N-myristoyltransferase (NMT) enzymes, in comparison to high metastatic 143B
osteosarcoma cells, in which nuclear Src is lower while myristoylation and NMT expression is very
high [46].
An intriguing hypothesis about the complex relationship between Src myristoylation and its
subcellular localization raises from the work of La Roux and coworkers [47], in which they discovered a
myristoil-binding site in the SH3 domain. The N-terminal myristoyl group can bind to this SH3 binding
site when Src is not anchored to the lipid layer, therefore the interaction of the myristoyl group with
lipids may prevent nuclear localization. Thus, intramolecular interactions involving SH3 -mediated
sequestering of the myristoyl group may be relevant in the context of Src nuclear localization [47].
4. Physiopathological Roles of Nuclear Src
Although tyrosine kinases are well known to function as signaling molecules downstream of
extracellular stimuli at the plasma membrane, some SFKs have been described to reside in the nucleus
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where they regulate tyrosine phosphorylation of nuclear proteins, and/or function as cofactor in
multiprotein complexes [48]. Therefore, the roles exerted by Src in the nucleus could be dependent or
not on its catalytic activity. Indeed, beside its capability to phosphorylate tyrosine residues on target
proteins, the SH2 and SH3 domains in the Src structure are involved in protein-protein interaction that
can be independent from Src activation status. In particular, nuclear Src seems to exacebate the activity
of oncogenes, and to counteract the protecting function of oncosuppressor, in general by inducing their
nuclear export. Here we reviewed the main mechanisms involving Src nuclear functions.
4.1. Regulation of Gene Transcription and Chromatin Architecture
Changes in the structure of nuclear compartment are frequently observed during transcription,
cell differentiation, senescence, cell cycle and tumorigenesis [49], and evidence of active nuclear Src has
been reported in different contexts. A study carried out on NT2D1 non-seminoma fibroblasts reveals
that Src phosphorylation is constitutively present in the nuclei of these cells, representing a downstream
effector of c-MET pathway [50]. c-MET is the membrane receptor of HGF (Hepatocyte Growth Factor).
HGF can increase the aggressive and malignant behavior of NT2D1 cells through c-MET activation [51].
The inhibition of Src deletes the HGF-dependent increase of cell proliferation rate, migration and
cell invasion. c-MET recruits Src when activated by HGF, and this stimulus seems to be a key point
allowing Src to translocate into the nucleus where it interacts with some gene promoters. In this context,
a pivotal role is played by the cancer microenvironment, given that in the culture basal conditions
(without administration of HGF) the inhibition of Src causes the augment of invasiveness but decreases
the cell proliferation rate and migration capability of mouse NT2D1 fibroblasts independently from
c-MET pathway, may be due to the Src recruitment by other homeostatic pathways controlling the
aggressiveness of these cells [50].
The idea that Src could interact with gene promoters is based on a study that explains a correlation
of SFKs with the chromatin structural changes observed following growth factors stimulation [52].
In this study, authors developed a pixel imaging technique of the nucleus to quantitatively detect
changes of chromatin structure and condensation levels. They demonstrated that SFK activation by
serum-conveyed growth factors localize into the nucleus more frequently in the euchromatin than the
heterochromatin areas, and that their kinase activity is required for the chromatin organization, given
that growth factor stimulation effects are avoided in mouse embryonic fibroblast SYF cells, which
are genetically deficient in expression of Src, Yes, Fyn and Lyn tyrosine kinases. Taken together, this
evidence suggested that the SFKs could be useful to create an “open” chromatin more accessible to
transcriptional factors [52]. In this context, we recently demonstrated the Src nuclear localization in
osteoblasts and low aggressive osteosarcoma cells [46], and in particular we observed nuclear Src
accumulation in hypocondensated chromatin, as demonstrated by the low DRAQ5 staining (Figure 2).
This finding, together with the work by Takahashi, strongly suggests a function for nuclear Src in the
regulation of transcription.
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As regards cancer cells, the protein p300, a large histone acetyltransferase with the function
of coactivator, was at first known to be a tumor suppressor but the recent discovery of p300 gene
mutations seems to suggest a role for this enzyme in the oncogenic transformation [53]. In the tumor
pancreatic environment, p300 seems to interact with Src, which can in turn activate the pro-migratory
genes such as HMGA2 and SMYD3 [54]. The binding of Src and p300 to the sequence of DNA depends
on chromatin and cell-type background. In those cancers in which Src has been found downregulated,
the clinical trials based on Src-inhibitor therapy have proven to be ineffective and data by Paladino et
al. provide some explanation about these failing therapies, as Src seems to be more involved in the
migratory pathway than in survival signaling. Although these works describe some peculiar roles of Src
in specific micro-environment, Src remains a good therapeutic target to prevent tumor metastasis [55].
4.2. Src-Dependent Regulation of Tumor Suppressors
As an example of its catalytic-dependent and independent nuclear functions, Src is able to
regulate the localization of INhibitor of Growth 1 (ING1) from nucleus to cytoplasm through
phosphorylation-dependent and independent mechanisms, thus contributing to alter the capability
of ING1 to induce apoptosis. ING1 plays a role in epigenetic regulation as tumor suppressor,
being a stoichiometric member of histone acetlytransferase (HAT) and histone deacetylase (HDAC)
complexes. When Src expression and/or activation is altered, as in many types of cancer, the ING1
levels are deregulated accordingly, and decreases following Src activation. Src destabilizes ING1 by
phosphorylation, thereby inducing its export from nucleus. The Src phosphorylation-independent
mechanism is based on the capacity of Src to bind directly ING1: in this role as cofactor, Src may
prompt the degradation of ING1, or, as an alternative, kinase-dead Src may recruit and/or activate
other tyrosine kinases to target this tumor suppressor [56].
Another protein that can be altered by Src-dependent kinase activity is the Runt domain
transcription factor 3 (RUNX3). RUNX3 is a transcription factor known to be a tumor suppressor
involved in proliferation, apoptosis and cellular differentiation. Oxidative stress causes RUNX3
mislocalization in cytoplasm in colon cancer cells. In conditions of oxidative stress, both Src expression
and activation is positively regulated in the nucleus by HDAC1, known to involved in the transcription
of oncogenes [57,58] and active Src phosphorylates RUNX3 leading to its cytoplasmic localization [59].
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4.3. Src and Estrogen Receptor
Studies on the subcellular localization of steroid receptors have demonstrated that they can have
effects other than the non-genomic action, thereby revealed their ability to interact with target effectors
and activate signaling pathways. Src is involved in the regulation of estrogen receptors, which are
known to regulate the homeostasis of a variety of tissues, including the bone [60]. Low levels of
estrogen deficiency lead to accelerated bone loss and this is the primary cause of postmenopausal
osteoporosis [61]. Estrogens are also responsible for an anti-apoptotic effect in osteoblasts [62].
Further studies have demonstrated that Src interacts with the estrogen receptor even in other cells such
as the uterine cells and human breast cancer cells. Indeed, in the nuclei of uterine cells, active Src can
phosphorylates estrogen receptor α (ERα) and enhances its transcriptional activity due to the activity of
SHP2 (Src-Homology Protein2) [63]. SHP2, a protein encoded by the gene PTPN11, is generally located
in the cytoplasm, but it is also known to translocate in the nucleus when DNA damage occurs [64].
SHP2 enhances Src tyrosine kinase activity by removing its inhibitory phosphorylation and Src, in turn,
phosphorylates ERα, thus allowing its binding to the progesterone receptor promoter and driving its
transcription [63].
Instead, the study of Castoria and colleagues demonstrates that in the breast cancer tumor
environment, Src can promote the tumor progression through its tyrosine kinase activity [65]. The Tyr
537 residue of ERα is a key regulatory site for its activity and localization, and also connects ERα with
Src [66]. The stimulation with estradiol promotes Src activity and leads to the phosphorylation of ERα
in Tyr537, thus driving the nuclear export of the receptor and regulating hormone responsiveness of
DNA synthesis in breast cancer cells [65].
4.4. Interaction with the Nuclear Envelope Protein Emerin
Emerin is a nuclear inner membrane protein whose gene mutations are related to Emery-Dreifuss
Muscular Dystrophy, an X-linked disease [67]. Tifft and coworkers demonstrated that emerin function
is regulated by several tyrosine kinases, including Her2, Src and Abl. In particular, Src can mediate
the signaling of Her2 by phosphorylation of three specific tyrosine residues in human emerin: Y59,
Y74 and Y95 [68]. These three amino acid residues could not be the only residues phosphorylated by
Src, since even the Y4, Y34, Y41, Y105 and Y155 are predicted Src-target sites [69]. Tifft and colleagues
demonstrated that the substitutions of the tyrosine with phenylalanine, in the sites recognized by
Src, reduced the capability of emerin to bind BAF (barrier-to-autointegration factor, also known as
BANF1), a conserved chromatin regulator that also binds lamins. Emerin binds proteins that are crucial
for the spatial organization of centrosome and nuclear structure, influences the actin cytoskeletal
dynamics and helps to fasten silent chromatin [70]. Emerin is also involved in the mechano-transduction
signaling, as it has been described as a downstream detector of mechanical stress. In more detail,
emerin binds Lamin A, another nuclear envelop protein, and emerin depletion leads to an increased
nuclear rigidity hindering the nuclear adaptation to mechanical forces. Guilluy and colleagues showed
that the phosphorylation of Y74 and Y95 of emerin residues by Src mediates the mechanical adaptation
of nuclei to mechanical force [71]. Some recent evidence demonstrate that the cells cultured on soft
matrices induced emerin phosphorylation and the mislocalization of nuclear envelope proteins in the
nucleoplasm [72]. The authors also suggest that emerin is able to reorganize the chromosome territories
in cells on softer matrix and they speculate that emerin phosphorylation acts as an upstream regulator
of lamin localization resulting in substantial changes of the transcriptional regulation in a substrate
stiffness-dependent manner [72].
4.5. Src and the Mechanotransduction
The involvement of cytoplasmic Src in the cell response to mechanical stimulation has been
well characterized, especially in its crucial role of triggering the tyrosine phosphorylation cascade
thought to be pivotal for mechanosensing [73]. Indeed, extracellular matrix proteins interaction
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with integrins induces their activation and the assembly of the focal adhesion complex proteins.
This process, known as cell mechanotransduction, identifies involved proteins as mechanosensors, able
to perceive and transduce mechanical stimuli into biochemical signals. Following integrin activation,
the membrane-bound Src is responsible of an increase in focal adhesion kinase (FAK) and paxillin
tyrosine phosphorylation, described as a first response to several mechanical stimuli, to such an extent
that Src and FAK inhibitors are able to block the response to mechanical stimulation as the cyclic
stretch [73].
In the context of mechanobiology, the Hippo pathway has been described to be relevant in
regulating tissue growth and organ size [74,75]. The main function of the Hippo pathway is to
inhibit Yes-associated proiein (YAP) and Tafazzin (TAZ) transcription co-activators, thereby regulating
cell proliferation, apoptosis, and stemness in response to extracellular and intracellular signals,
among which cell-cell contact, cell polarity, mechanical cues, ligands of G-protein coupled receptors
and cellular energy status [75]. When YAP and TAZ are slightly phosphorylated they are more
concentrated in the nucleus, thus leading to cell proliferation, wound healing or tissue regeneration [76].
Contrariwise, high levels of phosphorylation lead to cell quiescence [77]. It is also known that mechanical
signals and phosphorylation can modulate YAP1 functions [78]. This may be related to Src-mediated
phosphorylation of YAP1 in Tyr357 [79]. As a transcriptional factor, YAP1 is very important and two
types of pathway are involved in its regulation: the “canonical” way (through the negative LATS1/2
regulation) and, as recently discovered, the SFK dependent way [80].
Ege and colleagues described for the first time the dominance of YAP1 nuclear export as the
key point regulating its subcellular localization. Although serine phosphorylation is the first trigger
required for YAP1 nuclear export, the inhibition of SFK activity by dasatinib in cancer related fibroblasts
(CAFs) reduces the YAP1 nuclear localization leading to a higher citoplasmic content resembling
normal fibroblasts. Indeed, CAF treatment with Src-family kinase inhibitors, such as dasatinib, affects
the subcellular distribution of YAP1 by increasing the dissociation rate of YAP1 from chromatin thus
inducing YAP1 export from nucleus. Among Src-mediated control of YAP1, its phosphorylation in
Y357 functions as an independent mechanism for YAP1 activity regulation. Y357 phosphorylation
seems to be not involved in controlling YAP1 subcellular localization, but in reducing its transcriptional
competence. The evidence that YAP1 transcriptional activity is altered even when nuclear export is
blocked suggests that this crucial phosphorylation may occur in the nucleus and that depends on
nuclear Src activity [79].
Given the crucial roles of Src in the bone cells [20,23] and the great relevance of mechanical loads
in the bone homeostasis [81], it is worth to mention the nuclear Src functions in osteoblast cells in
response to mechanical stimulation. Indeed, external mechanical loads as the interstitial fluid shear
stress are sensed at the membrane by integrins that transmit the message through ERK, Src and RhoA
to actin stress fibers in the cytoskeleton [82]. Osteocytes, the most abundant cells of the bone tissue,
reside into the mineralized matrix and are capable of sensing mechanical cues applied to the bone, to
which they react triggering mechanisms involved in controlling osteoblast and osteoclast activities [83].
In particular, osteocytes respond to mechanical loading inducing the formation of a Src/Pyk2/MBD2
complex that suppresses anabolic gene expression [84]. Once activated by oscillatory fluid shear stress,
Pyk2 and Src translocate into the nucleus, where they associate with methyl-CpG-binding domain
protein 2 (MBD2), a protein involved in DNA methylation. Therefore, the formation of a nuclear
Pyk2/Src complex in osteocytes is related to altered transcription and epigenome regulation, leading
to the suppression of anabolic gene expression, likely a mechanism to prevent an over-reaction to
physical stimuli [84].
5. Prognostic Roles of Nuclear Src
Beside the aforementioned functions of nuclear Src, its subcellular localization in tumoral cells
has been associated to patient survival, being a useful prognostic factor.
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In our recent work, we described Src nuclear compartmentalization as a good prognosis factor for
osteosarcoma patients’ overall survival as assessed by tissue microarray analysis [46]. Indeed, a high
nuclear Src accumulation is detected in normal osteoblasts as well as in low-aggressive osteosarcoma
cell line SaOS2 cells, while its nuclear localization decreases in relationship to tumor aggressiveness,
being very low in high metastatic 143B cells. The regulation of the Src nuclear content in these cells
seems to be related to its myristoylation status, having myristoylated Src a prevalent cytoplasmic
localization. Indeed, the low NMT expression observed in low aggressive osteosarcoma cells can be
related to a reduced myristoylation of many proteins, other than Src. It is worth noting that high levels
of NMT expression have been associated to more aggressive tumors and NMT inhibitors are suggested
as potential chemotherapeutic agents [85,86].
In sight of this, further studies are needed to confirm the close relationship among Src nuclear
localization, the NMT expression and the osteosarcoma aggressiveness.
These results suggest that immunohistochemical analysis of Src subcellular localization, together
with its expression, can provide more accurate information in the assessment of osteosarcoma
prognosis [46].
In support of the prognostic relevance of nuclear Src in human tumors, Campbell and coauthors
demonstrated that phosphorylated Src in the nucleus is also associated with improved patient outcome
in estrogen receptor-positive tamoxifen-treated breast cancer [87].
This evidence seems to suggest that Src nuclear localization is associated to lower aggressiveness
in cancer. Interestingly, the aforementioned works (the only two cases in the literature providing
the prognostic relevance for Src subcellular localization) refer to osteosarcoma and estrogen
receptor-positive breast cancer, being the former a bone tumor and the latter a cancer with high
tropism to bone as its primary site of metastases [88].
Therefore, taken together, these works suggest peculiar Src nuclear functions in “bone-related”
tumors as a sort of “physiological” role that need further investigation.
6. Conclusions
The Src family of tyrosine kinases exerts a plethora of roles inside the cell, both at a physiological
and at a pathological level. In this review, we summarized the new emerging roles for Src recently
described to be located in the nuclear compartment and to interact with nuclear proteins. Noteworthily,
although the aforementioned works described a nuclear localization for Src, most of them did not
provide evidence about the mechanisms responsible of the shuttling into the nucleus. Staring from the
paper by David-Pfeuty et al., we speculated in this review about the importance of myristoylation status
as a crucial point involved in Src subcellular localization, emphasizing how myristoylated proteins are
anchored to the membrane, while the nuclear content of Src is the fraction of low-myristoylated proteins.
In the nucleus of normal and cancer cells, Src is involved in several activities involving both its
enzymatic activity as tyrosine kinase and its capability to interact with other protein thereby forming
protein complexes. In particular, Src participates in the regulation of chromatin reorganization and
transcriptional activity of transcription factors, in modulating nucleoskeleton shape in response to
mechanical stimulation by interacting with nuclear lamins and emerin, and it is surely involved in the
oncogenic transformation of tumoral cells, by repressing some oncosuppressors. It is worth noting that
Src nuclear functions can vary greatly depending on the type of assessed normal and/or tumor cells
and they are not solely related to increased cancer aggressiveness. Indeed, in osteosarcoma and in
hormone-positive breast cancer the Src nuclear compartmentalization is associated with improved
patients’ overall survival. This evidence suggests a sort of physiological relevance for Src nuclear
localization, confirmed by the high Src nuclear content observed in normal osteoblasts [46].
In summary, beside the well-known pivotal roles of Src and the other members of the family
exerted in the cell cytoplasmic compartment, also its more recently recognized nuclear subcellular
localization worth to be considered especially in the context of pathological conditions.
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